StreetInsider.com News Articles

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Wed, 02 Sep 2026 16:01:00 -0400

CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced that its Chief Scientific Officer, Elizabeth Buck, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, in New York, NY. In addition, the Company will host one-on-one meetings with investors on the same day.

Presentation details are as

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Wed, 02 Sep 2026 16:01:00 -0400

Presentation details are as

TD Cowen Reiterates Buy Rating on Black Diamond Therapeutics (BDTX)

Thu, 06 Aug 2026 09:12:16 -0400

TD Cowen analyst Marc Frahm reiterated a Buy rating on Black Diamond Therapeutics (NASDAQ: BDTX).

The analyst comments "BDTX reported Q2:26 net loss of $10MM and ended Q2 with cash of $110.5MM (into H2:28). Updated Ph2 NSCLC data at ASCO reinforced sile's activity across a range of EGFR NCMs including in the CNS. Preliminary mPFS of 15.2 months was generally competitive with firmo despite inclusion of broader mutations. Updated durability data + FDA feedback on pivotal path is expected in Q4. Remain Buy."

For an analyst ratings summary and ratings history on Black Diamond Therapeutics click here. For more ratings news

Jefferies Reiterates Buy Rating on Black Diamond Therapeutics (BDTX)

Thu, 06 Aug 2026 09:11:41 -0400

Jefferies analyst Maury Raycroft reiterated a Buy rating and $10.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).

The analyst comments "Two key catalysts are ahead in 4Q w/ updated silevertinib 1L longer-term follow-up in non-classical EGFRm NSCLC pts (venue TBD) and reg feedback for pivotal start. We caught up w/ mgmt for some add'l perspectives. Partnership discussions are ongoing to advance into both NSCLC and GBM pivotals. Ph.II RCT in newly diagnosed EGFR altered GBM to start in 4Q (safety lead-in portion enrolling currently). Cash $111M into 2H28. Big picture, we view the 4Q setup as attractive because: 1) the

Raymond James Reiterates Outperform Rating on Black Diamond Therapeutics (BDTX)

Thu, 06 Aug 2026 09:11:10 -0400

Raymond James analyst Sean McCutcheon reiterated an Outperform rating and $11.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).

The analyst comments "Wednesday, after market close, Black Diamond Therapeutics released 2Q26 and provided corporate updates. Management did not host a call. The company reported an 2Q26 net loss of $9.9M vs. our projected $9.0M. The ~$111M in cash and equivalents to end 2Q26 was guided to provide runway into 2H28 (unchanged). Initial PFS ~15.2 months for the ongoing Phase 2 trial in 1L non-classical EGFR mutation NSCLC for silevertinib was presented at ASCO on May 30 (see our commentary). Black Diamond

Stifel Reiterates Buy Rating on Black Diamond Therapeutics (BDTX)

Thu, 06 Aug 2026 09:10:48 -0400

Stifel analyst Laura Prendergast reiterated a Buy rating and $8.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX)

The analyst comments "The most impactful near-term catalyst will be a 4Q26 update on the Ph2 1L EGFRm NSCLC silevertinib data presented at ASCO 2026 along with FDA feedback on a pivotal path forward. We believe the Street is under appreciating the opportunity silevertinib could have in this setting and unfairly benchmarking the ASCO data set against small competitor data in more homogeneous (e.g., a few PACC mutations only), majority Asian patient populations. We view the breadth of mutations in which silevertinib has

Form 10-Q Black Diamond Therapeuti For: Jun 30

Wed, 05 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260805/26873857.html

Form 10-Q Black Diamond Therapeuti For: Jun 30

Wed, 05 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260805/26873857.html

Form 8-K Black Diamond Therapeuti For: Aug 05

Wed, 05 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260805/26873669.html

Form 8-K Black Diamond Therapeuti For: Aug 05

Wed, 05 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260805/26873669.html

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 05 Aug 2026 16:01:00 -0400

Presented positive Phase 2 results for silevertinib in frontline patients with non-classical EGFRm NSCLC at the 2026 ASCO Annual Meeting, including that no patients developed de novo brain metastases and that patients with baseline brain metastases achieved a CNS objective response rate of 86%
The results position silevertinib as a potential best-in-class brain-penetrant EGFR inhibitor; an update on the Phase 2 trial and FDA feedback on a pivotal development path for silevertinib in frontline patients with non-classical EGFRm NSCLC are anticipated in Q4 2026
Cash, cash equivalents, and investments of $110.5 million as of June 30, 2026,

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 05 Aug 2026 16:01:00 -0400

Presented positive Phase 2 results for silevertinib in frontline patients with non-classical EGFRm NSCLC at the 2026 ASCO Annual Meeting, including that no patients developed de novo brain metastases and that patients with baseline brain metastases achieved a CNS objective response rate of 86%
The results position silevertinib as a potential best-in-class brain-penetrant EGFR inhibitor; an update on the Phase 2 trial and FDA feedback on a pivotal development path for silevertinib in frontline patients with non-classical EGFRm NSCLC are anticipated in Q4 2026
Cash, cash equivalents, and investments of $110.5 million as of June 30, 2026,

Form SCHEDULE 13G Black Diamond Therapeuti Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:27:00 -0400
si-local-file:///var/storage/secattach/20260727/26820012.html

Form SCHEDULE 13G Black Diamond Therapeuti Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:27:00 -0400
si-local-file:///var/storage/secattach/20260727/26820012.html

Form SCHEDULE 13G/A Black Diamond Therapeuti Filed by: T. Rowe Price Investment Management, Inc.

Wed, 08 Jul 2026 11:30:00 -0400
si-local-file:///var/storage/secattach/20260708/26746229.html

Form SCHEDULE 13G/A Black Diamond Therapeuti Filed by: T. Rowe Price Investment Management, Inc.

Wed, 08 Jul 2026 11:30:00 -0400
si-local-file:///var/storage/secattach/20260708/26746229.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Behbahani Ali

Mon, 29 Jun 2026 16:40:00 -0400
si-local-file:///var/storage/secattach/20260629/26707097.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Behbahani Ali

Mon, 29 Jun 2026 16:40:00 -0400
si-local-file:///var/storage/secattach/20260629/26707097.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Kulkarni Samarth

Mon, 29 Jun 2026 16:38:00 -0400
si-local-file:///var/storage/secattach/20260629/26707042.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Kulkarni Samarth

Mon, 29 Jun 2026 16:38:00 -0400
si-local-file:///var/storage/secattach/20260629/26707042.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Menzel Garry E

Mon, 29 Jun 2026 16:37:00 -0400
si-local-file:///var/storage/secattach/20260629/26707028.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Menzel Garry E

Mon, 29 Jun 2026 16:37:00 -0400
si-local-file:///var/storage/secattach/20260629/26707028.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Raman Prakash

Mon, 29 Jun 2026 16:36:00 -0400
si-local-file:///var/storage/secattach/20260629/26707011.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Raman Prakash

Mon, 29 Jun 2026 16:36:00 -0400
si-local-file:///var/storage/secattach/20260629/26707011.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Dhingra Kapil

Mon, 29 Jun 2026 16:34:00 -0400
si-local-file:///var/storage/secattach/20260629/26706973.html